Literature DB >> 15533803

Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy.

Daniel Taussky1, Masoom Haider, Michael McLean, Ivan Yeung, Theresa Williams, Shannon Pearson, Gina Lockwood, Juanita Crook.   

Abstract

PURPOSE: Erectile dysfunction following permanent seed brachytherapy for prostate cancer may be related to the dose to the penile bulb. We investigated anatomic and dosimetric factors that might contribute to an increased dose to the penile bulb. METHODS AND MATERIALS: One-month CT and MR images were examined for 50 consecutive patients treated with exclusive (125)I permanent seed prostate brachytherapy to a prescribed dose of 145 Gy. Implants were preplanned by transrectal ultrasound (TRUS). Postimplant dosimetry was performed at 1 month using an MRI-CT fusion. Spearman's correlation was used to establish a correlation between dosimetric parameters, anatomical factors, and the dose to the penile bulb.
RESULTS: Penile bulb volumes ranged from 1.2-8.5 cc (median, 3.9 cc). The distance from the penile bulb to the prostate apex ranged from 5-33 mm (median, 15.5 mm). D50 of the penile bulb ranged from 13-121 Gy. The range for the V45 (65 Gy) was 0-87%; only 3% of patients had >2 cc covered by this isodose and in 16% of patients the V45 covered more than 50% of the penile bulb. About one-third of the patients received a dose to the bulb that would put them at a high risk of erectile dysfunction after external beam radiation, if the dose were radiobiologically equivalent. There was a significant inverse correlation between the distance between the prostate apex and the penile bulb, and the dosimetric parameters of the bulb: r = -0.548, -0.656, p = < 0.01. The further caudal the apex was from the symphysis, the closer it was to the penile bulb (r = -0.564, p = <0.01). We could not find a correlation between the dose to the prostate or its apex and the dose to the penile bulb.
CONCLUSION: When the prostate apex is close to the penile bulb, care should be taken to limit the dose to the penile bulb, if possible. This may reduce the incidence of erectile dysfunction and urinary toxicity after permanent seed prostate brachytherapy.

Entities:  

Mesh:

Year:  2004        PMID: 15533803     DOI: 10.1016/j.brachy.2004.06.004

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  3 in total

1.  Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds.

Authors:  V Morillo; J L Guinot; I Tortajada; J V Ricós; L Arribas; M Maroñas; M Estornell; J Casanova
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

Review 2.  The current role of imaging for prostate brachytherapy.

Authors:  Brendan Carey; Sarah Swift
Journal:  Cancer Imaging       Date:  2007-02-28       Impact factor: 3.909

3.  Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging.

Authors:  Ima Paydar; Brian S Kim; Robyn A Cyr; Harriss Rashid; Amna Anjum; Thomas M Yung; Siyuan Lei; Brian T Collins; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2015-09-01       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.